BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 21909982)

  • 1. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer.
    Tokuda E; Seino Y; Arakawa A; Saito M; Kasumi F; Hayashi S; Yamaguchi Y
    Breast Cancer Res Treat; 2012 Jun; 133(2):427-36. PubMed ID: 21909982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
    Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
    Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells.
    Azuma K; Urano T; Horie-Inoue K; Hayashi S; Sakai R; Ouchi Y; Inoue S
    Cancer Res; 2009 Apr; 69(7):2935-40. PubMed ID: 19318565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.
    Sui M; Huang Y; Park BH; Davidson NE; Fan W
    Cancer Res; 2007 Jun; 67(11):5337-44. PubMed ID: 17545614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer.
    Saji S; Kawakami M; Hayashi S; Yoshida N; Hirose M; Horiguchi S; Itoh A; Funata N; Schreiber SL; Yoshida M; Toi M
    Oncogene; 2005 Jun; 24(28):4531-9. PubMed ID: 15806142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
    Chang J; Sui M; Fan W
    Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The WT1 Wilms' tumor suppressor gene product interacts with estrogen receptor-alpha and regulates IGF-I receptor gene transcription in breast cancer cells.
    Reizner N; Maor S; Sarfstein R; Abramovitch S; Welshons WV; Curran EM; Lee AV; Werner H
    J Mol Endocrinol; 2005 Aug; 35(1):135-44. PubMed ID: 16087727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
    Sui M; Jiang D; Hinsch C; Fan W
    Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel.
    Jin Y; Hu W; Liu T; Rana U; Aguilera-Barrantes I; Kong A; Kumar SN; Wang B; Gao P; Wang X; Duan Y; Shi A; Song D; Yang M; Li S; Han B; Zhao G; Fan Z; Miao QR
    Cancer Lett; 2018 Apr; 419():233-244. PubMed ID: 29373839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The vitamin A family can significantly decrease the expression of ERbeta of ERs positive breast cancer cells in the presence or absence of ER ligands and paclitaxel.
    Czeczuga-Semeniuk E; Jarzabek K; Lemancewicz D; Wołczyński S
    Gynecol Endocrinol; 2009 May; 25(5):287-93. PubMed ID: 19340624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells.
    Zhao C; Matthews J; Tujague M; Wan J; Ström A; Toresson G; Lam EW; Cheng G; Gustafsson JA; Dahlman-Wright K
    Cancer Res; 2007 Apr; 67(8):3955-62. PubMed ID: 17440111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes.
    Moggs JG; Murphy TC; Lim FL; Moore DJ; Stuckey R; Antrobus K; Kimber I; Orphanides G
    J Mol Endocrinol; 2005 Apr; 34(2):535-51. PubMed ID: 15821115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.
    Zhang B; Zhang X; Tang B; Zheng P; Zhang Y
    Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer.
    Yoshimoto N; Toyama T; Takahashi S; Sugiura H; Endo Y; Iwasa M; Fujii Y; Yamashita H
    Breast Cancer Res Treat; 2011 Nov; 130(1):331-9. PubMed ID: 21755340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
    Chong K; Subramanian A; Sharma A; Mokbel K
    Anticancer Res; 2011 Jan; 31(1):23-32. PubMed ID: 21273576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status.
    Travaglini L; Vian L; Billi M; Grignani F; Nervi C
    Int J Biochem Cell Biol; 2009 Jan; 41(1):225-34. PubMed ID: 18789398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo.
    Zhang W; Wang L; Fan Q; Wu X; Wang F; Wang R; Ma Z; Yang J; Lu SH
    Oncol Rep; 2011 Sep; 26(3):621-8. PubMed ID: 21687957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.